TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19691461

Group type: EXPERIMENTAL
Intervention: Aciclovir (ACV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other antiviral agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of shingles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different classes of drugs for post-herpetic neuralgia
Number of subjects: 0
Study: 17224202

Group type: EXPERIMENTAL
Intervention: Low glycaemic index cereal
Number of subjects: 64

Group type: COMPARATOR
Intervention: High glycaemic index cereal
Number of subjects: 64
Study: 15575055

Group type: EXPERIMENTAL
Intervention: Double-embryo transfer
Number of subjects: 661

Group type: COMPARATOR
Intervention: Single-embryo transfer
Number of subjects: 661
Study: 11276371

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage (GM)-CSF
Number of subjects: 35

Group type: COMPARATOR
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: GM-CSF followed by G-CSF
Number of subjects: 35
Study: 9389268

Group type: EXPERIMENTAL
Intervention: Colour kinesis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional TOE method
Number of subjects: 60
Study: 7947191

Group type: EXPERIMENTAL
Intervention: 1 application of SPF 25 sunscreen
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 4 applications of SPF 25 sunscreen
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 5 applications of SPF 25 sunscreen
Number of subjects: 98
Study: 3145357

Group type: EXPERIMENTAL
Intervention: VACA chemotherapy (vincristine, actinomycin D, cyclophosphamide, and adriamycin) with local control via surgery and/or radiation
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: VAIA chemotherapy (high doses of ifosfamide with mesna uroprotection)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Conventional fractionation or accelerated split‐course hyperfractionation (randomized for patients with radiation)
Number of subjects: 93
Study: 30566760

Group type: COMPARATOR
Intervention: Curcumin (CUR) 180 mg/d for 7 days before exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Curcumin (CUR) 180 mg/d for 7 days after exercise
Number of subjects: 10
Study: 29092078

Group type: EXPERIMENTAL
Intervention: Sodium selenite 300 µg/d po + Methimazole (MMI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo + Methimazole (MMI)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sodium selenite + Methimazole (MMI)
Number of subjects: 70
Study: 25307674

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 23811682

Group type: EXPERIMENTAL
Intervention: Highly purified eicosapentaenoic acid (EPA) 1,800 mg/day for 6 months
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (no EPA treatment)
Number of subjects: 144
Study: 19766643

Group type: EXPERIMENTAL
Intervention: Baseline laboratory tests and histologic data
Number of subjects: 1050
Study: 18199388

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (2.9 g n-3 LCPUFA/d)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 100
Study: 15746685

Group type: EXPERIMENTAL
Intervention: Forceps delivery combined with mediolateral episiotomy
Number of subjects: 5377

Group type: EXPERIMENTAL
Intervention: High birth weight
Number of subjects: 5377

Group type: EXPERIMENTAL
Intervention: Episiotomy
Number of subjects: 5377

Group type: EXPERIMENTAL
Intervention: Prolonged first and second stages of labor
Number of subjects: 5377

Group type: EXPERIMENTAL
Intervention: Low parity
Number of subjects: 5377
Study: 12761604

Group type: EXPERIMENTAL
Intervention: Individual academic detailing visits (2 visits on NSAIDs)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Group academic detailing visits (2 visits during local quality group meetings)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Individual academic detailing visits
Number of subjects: 184

Group type: COMPARATOR
Intervention: Group academic detailing visits
Number of subjects: 184
Study: 10374155

Group type: EXPERIMENTAL
Intervention: Limbal approach for primary posterior capsulectomy and anterior vitrectomy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Pars plana approach for primary posterior capsulectomy and anterior vitrectomy
Number of subjects: 38
Study: 9082343

Group type: EXPERIMENTAL
Intervention: Cirrhosis of the liver
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chronic active hepatitis (CAH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 30
Study: 1676932

Group type: EXPERIMENTAL
Intervention: MK-458 (up to 60 mg per day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa
Number of subjects: 19
Study: 6352636

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tobramycin plus carbenicillin
Number of subjects: 28
Study: 30762806

Group type: EXPERIMENTAL
Intervention: 1 g single dose of azithromycin
Number of subjects: 460

Group type: COMPARATOR
Intervention: 100 mg doxycycline twice daily for 7 days
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 460
Study: 29180640

Group type: EXPERIMENTAL
Intervention: CSII combined with metformin therapy
Number of subjects: 188

Group type: COMPARATOR
Intervention: CSII therapy
Number of subjects: 188
Study: 26913382

Group type: EXPERIMENTAL
Intervention: First-episode psychosis patients with nonauditory hallucinations
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group without nonauditory hallucinations
Number of subjects: 67
Study: 25060113

Group type: EXPERIMENTAL
Intervention: Water campaign intervention
Number of subjects: 1288
Study: 20740300

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg oral dose) with ketoconazole (400 mg/day for 7 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Axitinib (5 mg oral dose) alone
Number of subjects: 32
Study: 19673008

Group type: EXPERIMENTAL
Intervention: Active Referral‐‐4 outcalls
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Active Referral‐‐1 outcall
Number of subjects: 571

Group type: COMPARATOR
Intervention: Passive Referral (Control)
Number of subjects: 571
Study: 18078888

Group type: EXPERIMENTAL
Intervention: Combined sciatic nerve block and continuous '3-in-1' block with bupivacaine (group TS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous '3-in-1' block with bupivacaine (group T)
Number of subjects: 30
Study: 16280277

Group type: EXPERIMENTAL
Intervention: UACR above the median value of 1.406
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: AV sclerosis
Number of subjects: 960
Study: 12011966

Group type: EXPERIMENTAL
Intervention: HR (Paroven-Venoruton; 0-(beta-hydroxyethyl)-rutosides) 2 g/day for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10215707

Group type: EXPERIMENTAL
Intervention: Pulsed-wave Doppler
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Transverse continuous-wave Doppler
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Longitudinal continuous-wave Doppler
Number of subjects: 45

Group type: COMPARATOR
Intervention: Thermodilution technique
Number of subjects: 45
Study: 8580948

Group type: EXPERIMENTAL
Intervention: Unilateral eccentric weight training (8 weeks, 3 times per week, 3-5 sets of six repetitions)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Unilateral eccentric weight training
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Detraining (8 weeks after training)
Number of subjects: 17
Study: 2395047

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 85988

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (E.A.C.A.), 36 g/day
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (no antifibrinolytic drug)
Number of subjects: 165
Study: 31957601

Group type: EXPERIMENTAL
Intervention: Appreciative Inquiry intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 31362109

Group type: EXPERIMENTAL
Intervention: aPDT with TBO+635 nm diode laser
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: aPDT with ICG+808 nm diode laser
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TBO alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 28121741

Group type: EXPERIMENTAL
Intervention: Everolimus plus reduced-dose tacrolimus (EVR + rTAC)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Standard tacrolimus (TAC-C)
Number of subjects: 211
Study: 26686042

Group type: EXPERIMENTAL
Intervention: COST measure (financial toxicity score range 0-44)
Number of subjects: 100
Study: 23307042

Group type: EXPERIMENTAL
Intervention: LA group: lansoprazole (LPZ) 30 mg 4 times a day + amoxicillin (AMPC) 500 mg 4 times a day for two weeks
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: LAL group: LPZ 30 mg twice a day + AMPC 750 mg twice a day + levofloxacin (LVFX) 300 mg twice a day for one week
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: LAS group: LPZ 30 mg twice a day + AMPC 750 mg twice a day + sitafloxacin (STFX) 100 mg twice a day for one week
Number of subjects: 204
Study: 21505377

Group type: COMPARATOR
Intervention: Booklet only
Number of subjects: 338

Group type: COMPARATOR
Intervention: Rehabilitation only
Number of subjects: 338
Study: 19340904

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 68

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 68
Study: 16525224

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0
Study: 14741858

Group type: EXPERIMENTAL
Intervention: Students who received the names of stations prior to the OSCE (n=20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Students who did not receive the names of stations prior to the OSCE (n=40)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Students who received the names of stations prior to the OSCE
Number of subjects: 60

Group type: COMPARATOR
Intervention: Students who did not receive the names of stations prior to the OSCE
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 11108761

Group type: EXPERIMENTAL
Intervention: Extended Stroke Unit Service (ESUS)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Ordinary Stroke Unit Service (OSUS)
Number of subjects: 320
Study: 9368828

Group type: EXPERIMENTAL
Intervention: Prophylactic use of ursodiol
Number of subjects: 0
Study: 1375826

Group type: EXPERIMENTAL
Intervention: Grid laser treatment
Number of subjects: 1

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1
Study: 3963846

Group type: EXPERIMENTAL
Intervention: Bestatin
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control
Number of subjects: 101
Study: 27533623

Group type: EXPERIMENTAL
Intervention: ALC group
Number of subjects: 88

Group type: COMPARATOR
Intervention: Non-ALC group
Number of subjects: 88
Study: 27727241

Group type: EXPERIMENTAL
Intervention: Direct-current (DC) stimulation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-frequency alternating-current (AC) stimulation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 45
Study: 25924421

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reflexology
Number of subjects: 40
Study: 22610178

Group type: EXPERIMENTAL
Intervention: Fluid-conservative therapy
Number of subjects: 931

Group type: COMPARATOR
Intervention: Fluid-liberal therapy
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Increase in plasma angiopoietin-2 levels from day 0 to day 3
Number of subjects: 931
Study: 20565154

Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Standard treatment with frequent urine toxicology monitoring
Number of subjects: 193
Study: 18460957

Group type: EXPERIMENTAL
Intervention: Quick Read (QR)-CRP test
Number of subjects: 50

Group type: COMPARATOR
Intervention: Absolute neutrophil count
Number of subjects: 50

Group type: COMPARATOR
Intervention: White blood cell count
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of QR-CRP, absolute neutrophil count, and white blood cell count
Number of subjects: 50
Study: 15989932

Group type: EXPERIMENTAL
Intervention: Verbal self‐ordered pointing test
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Non‐verbal self‐ordered pointing test
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verbal span task
Number of subjects: 24
Study: 15558389

Group type: EXPERIMENTAL
Intervention: Arm-crank rehabilitation training program (6 weeks) in addition to traditional rehabilitation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Traditional rehabilitation only
Number of subjects: 14
Study: 11772270

Group type: EXPERIMENTAL
Intervention: Bismuth-based triple therapy monocapsule (Helicide) containing bismuth, tetracycline, and metronidazole.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bismuth-based triple therapy (without the monocapsule) including bismuth, tetracycline, and metronidazole.
Number of subjects: 0
Study: 9203211

Group type: EXPERIMENTAL
Intervention: Urine free beta hCG
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Urine beta core
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Urine total oestriol
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Maternal serum free beta hCG
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Nuchal translucency
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Urine total oestriol combined with maternal age
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Urine beta core combined with maternal age
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Urine free beta hCG combined with maternal age
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Maternal serum free beta hCG combined with maternal age
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Urine total oestriol combined with nuchal translucency
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Urine beta core combined with nuchal translucency
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Urine free beta hCG combined with nuchal translucency
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Maternal serum free beta hCG combined with nuchal translucency
Number of subjects: 416
Study: 7966807

Group type: EXPERIMENTAL
Intervention: Duplex ultrasonography
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Air plethysmography (APG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Photoplethysmography (PPG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Venous filling index
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Residual volume fraction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Kappa coefficient of agreement
Number of subjects: 20
Study: 3325395

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d.
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 29720161

Group type: EXPERIMENTAL
Intervention: Training program for ASHAs on hypertension management
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Community-based education support groups led by ASHAs
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Training materials for ASHAs
Number of subjects: 15
Study: 27884124

Group type: EXPERIMENTAL
Intervention: SMS intervention (ten messages delivered three times over two weeks)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: IS intervention (one session immediately after pretest)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Combined SMS and IS intervention
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 350
Study: 25084108

Group type: EXPERIMENTAL
Intervention: Nanofilled resin composite (Filtek Z350, 3M ESPE)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nanohybrid resin composite (Esthet‐X, Dentsply)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Microhybrid resin composite (Filtek Z250, 3M ESPE)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Comparison of three composites after 54 months
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall performance of materials
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Secondary caries and postoperative sensitivity
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Marginal adaptation
Number of subjects: 41
Study: 22321056

Group type: COMPARATOR
Intervention: PXG group
Number of subjects: 53

Group type: COMPARATOR
Intervention: PXS group
Number of subjects: 53

Group type: COMPARATOR
Intervention: PXS, PXG, and control groups
Number of subjects: 53
Study: 20806180

Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 478
Study: 18762707

Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 0
Study: 16381993

Group type: EXPERIMENTAL
Intervention: GH treatment for 9 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 30
Study: 14658975

Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 40
Study: 10799368

Group type: EXPERIMENTAL
Intervention: Isolated soy protein (ISP) 50:0 g
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Isolated soy protein (ISP) 40:10 g
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Isolated soy protein (ISP) 30:20 g
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Isolated soy protein (ISP) 20:30 g
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (casein 0:50 g)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Isolated soy protein (ISP) 30 g
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Isolated soy protein (ISP) 40 g
Number of subjects: 81
Study: 8970834

Group type: EXPERIMENTAL
Intervention: Bioartificial liver (BAL) treatment for FHF patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bioartificial liver (BAL) treatment for chronic liver failure patients
Number of subjects: 20
Study: 1568544

Group type: EXPERIMENTAL
Intervention: Effervescent citrate-cimetidine combination (200 mg cimetidine/tablet)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Liquid aluminium-magnesium hydroxide antacid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2860133

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 29931231

Group type: EXPERIMENTAL
Intervention: Synbiotic yogurt (300 g daily containing 108 colony-forming units Bifidobacterium animalis/mL and 1.5 g inulin)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Conventional yogurt (daily)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Healthy lifestyle advice (control group)
Number of subjects: 102
Study: 27803925

Group type: EXPERIMENTAL
Intervention: VAWI treatment (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Basic treatment (group A)
Number of subjects: 40
Study: 24815948

Group type: EXPERIMENTAL
Intervention: Positive valence words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High arousal words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium and low arousal words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral and negative words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early posterior negativity (EPN) in ERPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arousal
Number of subjects: 0
Study: 22112212

Group type: EXPERIMENTAL
Intervention: Supplementary native language discharge summary
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (English discharge summary)
Number of subjects: 130
Study: 20537164

Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg flat dose, subcutaneously)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 44
Study: 18930575

Group type: EXPERIMENTAL
Intervention: Laser fluorescence device (DIAGNOdent pen, KaVo)
Number of subjects: 120
Study: 16195054

Group type: EXPERIMENTAL
Intervention: Inference-based approach (IBA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cognitive appraisal model (CAM)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Exposure and response prevention (ERP)
Number of subjects: 54
Study: 11830196

Group type: EXPERIMENTAL
Intervention: Direct thrombin inhibitors (hirudin, bivalirudin, argatroban, efegatran, or inogatran)
Number of subjects: 35970

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 35970
Study: 10622066

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori test-and-treat strategy
Number of subjects: 232

Group type: COMPARATOR
Intervention: Referral to direct access endoscopy (control)
Number of subjects: 232
Study: 7781397

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy, magnetic resonance imaging, endoesophageal ultrasound, and/or surgical staging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase 2 trials of chemoradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized multi‐institutional trials
Number of subjects: 0
Study: 2160665

Group type: EXPERIMENTAL
Intervention: Porcine ACTH 1-39 (1.5 U)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: h-CRH (25 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7006236

Group type: EXPERIMENTAL
Intervention: Mexiletine treatment
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 31736439

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 38
Study: 31196501

Group type: EXPERIMENTAL
Intervention: Elental® (treatment group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control diet (control group)
Number of subjects: 22